Table. 4-1. Effect of FMAC on cyclophosphamide- or 5- fluorouracil-treated mice spleen weight and blood leukocyte.

Drug	Dose (g /kg)	Spleen (g)	WBC (10^3μl)
Control		0.12 ± 0.01	9.7 ± 1.0
Cyclophosphamide	+ H_2O	0.06 ± 0.0$^{###}$	2.6 ± 0.1$^{###}$
	+ FMAC 0.5	0.05 ± 0.01	3.2 ± 0.7
	+ FMAC 2.0	0.08 ± 0.01	2.5 ± 0.5
Control		0.12 ± 0.02	12.8 ± 1.5
5- Fluorouracil	+ H_2O	0.06 ± 0.01$^{##}$	9.0 ± 2.0$^{#}$
	+ FMAC 0.5	0.06 ± 0.00	6.1 ± 0.8
	+ FMAC 2.0	0.06 ± 0.00	6.5 ± 0.9

All values are means ± S.E. (n = 7). $^{#}$P<0.05, $^{##}$P<0.01, $^{###}$P<0.001 compared with control group.

Table. 4-2. Effect of FMAC on body weight and urine volume of cisplatin treated rats.

Drug	Dose (g /kg)	Initial bw. (g)	Final bw. (g)	Urine Volume (ml / 24 hr)
Control		267.29 ± 5.28	335.3 ± 8.5	33. 7 ± 1.8
Cisplatin	+ H_2O	266.43 ± 3.18	304.1 ± 8.4$^{#}$	54.5 ± 6.0$^{#}$
	+ FMAC 0.5	276.14 ± 3.71	275.6 ± 11.0	38.0 ± 2.6*
	+ FMAC 2.0	267.43 ± 2.69	289.3 ± 4.2	48.0 ± 9.5

All values are means ± S.E. (n=7). $^{#}$P<0.05 compared with control group.

*P<0.05 compared with cisplatin + H_2O group.

bw: body weight

Table. 4-3. Effect of FMAC on cisplatin treated rats blood urea nitrogen and urine creatinine clearance.

Drug	Dose (g / kg)	Blood Urea Nitrogen (mg / dl)	Creatinine Clearance (ml / h / 100 g bw)
Control		21.93 ± 1.63	8.46 ± 0.59
Cisplatin + H_2O		59.84 ± 4.65$^{###}$	2.69 ± 0.34$^{###}$
+ FMAC	0.5	43.61 ± 2.84**	3.26 ± 0.37
+ FMAC	2.0	50.10 ± 3.55	3.05 ± 0.35

All values are means ± S.E. (n=7). $^{###}$P<0.01 compared with control group. **P<0.01 compared with cisplatin + H_2O group.

Table. 4-4. Effect of FMAC on contents of malondialdehyde (MDA), glutathione and protein in the kidney of cisplatin treated rats.

Drug	Dose	MDA (nmol/mg protein)	GSH (μmol /g tissue)	Protein (mg / g tissue)
Control		0.85 ± 0.16	0.25 ± 0.02	146.01 ± 3.85
Cisplatin + H_2O		1.61 ± 0.11$^{##}$	0.70 ± 0.13$^{##}$	126.03 ± 6.44$^{#}$
+ FMAC	0.5	1.50 ± 0.11	0.84 ± 0.07	143.29 ± 3.84*
+ FMAC	2.0	1.13 ± 0.01	0.65 ± 0.08	133.51 ± 4.27

All values are means ± S.E. (n=7). $^{#}$P<0.05, $^{##}$P<0.01 compared with control group. *p< compared with cisplatin + H_2O group.

Table. 4-5.. Effect of FMAC on carrageenan induced rat paw edema.

Time (min)	Increaed Volume (ml)			
	Control	FMAC		Indomethacin
		0.5 g / kg	2.0g /kg	10 mg/kg
40	0.22 ± 0.02	0.34 ± 0.02	0.28 ± 0.05	0.29 ± 0.05
80	0.55 ± 0.09	0.62 ± 0.03	0.56 ± 0.06	0.36 ± 0.06
120	0.92 ± 0.06	1.06 ± 0.04	0.98 ± 0.06	0.54 ± 0.07**
180	1.06 ± 0.09	1.23 ± 0.05	1.26 ± 0.05	0.70 ± 0.09*
240	0.98 ± 0.08	1.14 ± 0.05	1.09 ± 0.04	0.76 ± 0.06
300	1.00 ± 0.10	1.07 ± 0.07	1.01 ± 0.05	0.83 ± 0.08

All values are means ± S.E. (n = 8). *P<0.05, **P<0.01 compared with control group.

Table. 4-6. Effect of FMAC on plasma extravasation response to compound 48/80, bradykinin and prostaglandin E_2 in rat skin.

Drug	Dose (g / kg)	μg Evan Blue		
		Compound 48/80	Bradykinin	Prostaglandin E_2
Control	-	182.7 ± 28.5	75.8 ± 4.9	40.0 ± 2.9
FMAC	0.5	126.5 ± 21.2	88.2 ± 3.9	38.9 ± 2.2
FMAC	2.0	105.1 ± 9.8*	91.0 ± 9.3	48.4 ± 6.2

All values are means ± S.E. (n=7). *P<0.01 compared with control group

Table. 4-7. Effect of FMAC on adjuvant arthritis in rats.

Drug	Dose (g / kg)	Right foot volume (ml)	
		Before	24 th day
Native Control	-	168 ± 0.02	2.10 ± 0.04
Control	-	1.68 ± 0.02	3.03 ± 0.09
FMAC	0.5	1.64 ± 0.04	3.09 ± 0.05
FMAC	2.0	1.63 ± 0.04	2.85 ± 0.04
Indomethacin	2.0	1.70 ± 0.02	2.59 ± 0.11

All values are means ± S.E.

Table. 4-8. Effect of FMAC on type I – IV allergic reaction.

Drug	Does (g / kg)	μg Evan Blue			
		Type I	Type II	Type III	Type IV
Control	-	128.3 ± 12.1	19.5 ± 1.3	57.6 ± 3.3	17.0 ± 0.7
FMAC	0.5	178.5 ± 23.9	20.5 ± 2.3	50.4 ± 5.0	15.5 ± 0.4
FMAC	2.0	165.5 ± 23.3	23.5 ± 2.5	59.7 ± 9.1	14.7 ± 0.3**

All values are means ±S.E. (n = 7) **P<0.01 compared with control group